INSMED INCORPORATED (NASDAQ:INSM) Files An 8-K Regulation FD DisclosureItem 7.01. Regulation FD Disclosure.
As previously announced,Insmed Incorporated (the “Company”) will host an Analyst and Investor Day in New York City on the date hereof, and a live webcast of the event will be available through the investor relations section of the Company’s website. The slide presentation to be used by the Company during the Analyst and Investor Day is attached hereto as Exhibit99.1 and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
|
Exhibit No.
|
Description
|
|
99.1
|
Insmed Incorporated Analyst and Investor Day Presentation, dated July19, 2017.
|
INSMED Inc ExhibitEX-99.1 2 a17-18012_1ex99d1.htm EX-99.1 Exhibit 99.1 Welcome & Opening Remarks Will Lewis,…To view the full exhibit click here
About INSMED INCORPORATED (NASDAQ:INSM)
Insmed Incorporated is a biopharmaceutical company. The Company operates in the segment of development and commercialization of inhaled therapies for patients with serious lung diseases. The Company’s lead product candidate, ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for patients with nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. The Company’s earlier stage pipeline includes INS1009, a nebulized prodrug formulation of treprostinil, a vasodilator of pulmonary arterial vascular beds. The Company is conducting a global Phase III clinical study of ARIKAYCE (the 212 or CONVERT study) in adult patients with NTM lung disease caused by Mycobacterium avium complex (MAC), the infective species in NTM lung disease in the United States, Europe and Japan.